Literature DB >> 27484771

The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.

Esther Diana Rossi1, Tommaso Bizzarro2, Sara Granja3,4, Maurizio Martini2, Sara Capodimonti2, Emilia Luca2, Guido Fadda2, Celestino Pio Lombardi5, Alfredo Pontecorvi6, Luigi Maria Larocca2, Fatima Baltazar3,4, Fernando Schmitt7,8,9.   

Abstract

BRAF V600E mutation, usually performed by DNA techniques, is one of the most common diagnostic markers in papillary thyroid carcinoma. Few papers have demonstrated that plump cells (eosinophilic cytoplasms and papillary thyroid carcinoma nuclei) and peculiar sickle-shaped nuclei represent morphological features of BRAF V600E on papillary thyroid carcinomas. These features seem to be linked to glycolytic phenotype whereby monocarboxylate transporters 1-4 are hypothesized to have a dominant role as lactate transporters. We investigated the association between these morphological features and monocarboxylate transporters 1 and 4 in 48 cyto-histological samples diagnosed as "positive for malignancy-favoring papillary thyroid carcinoma". These cases were processed with liquid-based cytology and underwent BRAF V600E mutational analysis (pyrosequencing) on liquid-based cytology and monocarboxylate transporters immunostaining on histology. The expression of monocarboxylate transporter 1, monocarboxylate transporter 4, glucose trasporter-1 and carbonic anhidrase were scored semi-quantitatively with expression from 0 to 3+ (strong positivity). The 33 mutated and 15 wild type cases showed 100 % cyto-histological concordance. The cytological evaluation revealed plump cells and sickle nuclear shape in 100 % mutated cases. Monocarboxylate transporter 1 yielded 76 % positivity in the mutated cases especially in both the plump cells and sickle-shaped nuclei, whereas the wild types showed 13.3 % positive monocarboxylate transporter 1 (p = 0.00013). Monocarboxylate transporter 4 resulted in 100 % positivity in mutated and 40 % in wild types (p < 0.005). Furthermore, 20 % of the wild types showed weak monocarboxylate transporter 1 nuclear expression associated to a less aggressive behavior. The analysis of glucose trasporter-1 and carbonic anhidrase did not highlight any statistical significance (p > 0.05). This is the first report analyzing the association between monocarboxylate transporter expression and the morphological features of BRAF V600E mutated papillary thyroid carcinomas suggesting the possible involvement of lactate in the morphological features.

Entities:  

Keywords:  BRAF V600E mutation; Liquid-based cytology; MCTs; PTC; Plump cells; Thyroid lesions

Mesh:

Substances:

Year:  2016        PMID: 27484771     DOI: 10.1007/s12020-016-1044-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Authors:  Imanol Arozarena; Berta Sanchez-Laorden; Leisl Packer; Cristina Hidalgo-Carcedo; Robert Hayward; Amaya Viros; Erik Sahai; Richard Marais
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

2.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  The Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Edmund S Cibas; Syed Z Ali
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 4.  Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.

Authors:  Anne M Strohecker; Eileen White
Journal:  Cancer Discov       Date:  2014-05-23       Impact factor: 39.397

5.  Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.

Authors:  Alexander Finkelstein; Gillian H Levy; Pei Hui; Avinash Prasad; Renu Virk; David C Chhieng; Tobias Carling; Sanziana A Roman; Julie A Sosa; Robert Udelsman; Constantine G Theoharis; Manju L Prasad
Journal:  Histopathology       Date:  2012-02-15       Impact factor: 5.087

Review 6.  Molecular diagnostics of thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

Review 7.  The nightmare of indeterminate follicular proliferations: when liquid-based cytology and ancillary techniques are not a moon landing but a realistic plan.

Authors:  Esther Diana Rossi; Guido Fadda; Fernando Schmitt
Journal:  Acta Cytol       Date:  2014-07-16       Impact factor: 2.319

Review 8.  Molecular diagnostics and predictors in thyroid cancer.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 9.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

10.  Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization.

Authors:  Céline Pinheiro; Valter Penna; Filipa Morais-Santos; Lucas F Abrahão-Machado; Guilherme Ribeiro; Emílio C Curcelli; Marcus V Olivieri; Sandra Morini; Isabel Valença; Daniela Ribeiro; Fernando C Schmitt; Rui M Reis; Fátima Baltazar
Journal:  J Transl Med       Date:  2014-05-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.